Leerink Partnrs Issues Positive Forecast for Bruker Earnings

Bruker Co. (NASDAQ:BRKR) – Stock analysts at Leerink Partnrs raised their FY2024 earnings estimates for shares of Bruker in a research report issued to clients and investors on Tuesday, January 21st. Leerink Partnrs analyst P. Souda now forecasts that the medical research company will post earnings of $2.39 per share for the year, up from their prior estimate of $2.38. The consensus estimate for Bruker’s current full-year earnings is $2.39 per share. Leerink Partnrs also issued estimates for Bruker’s Q4 2024 earnings at $0.74 EPS, Q4 2025 earnings at $0.91 EPS, FY2025 earnings at $2.74 EPS, FY2026 earnings at $3.16 EPS and FY2027 earnings at $3.65 EPS.

Bruker (NASDAQ:BRKR) last released its quarterly earnings results on Tuesday, November 5th. The medical research company reported $0.60 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.61 by ($0.01). Bruker had a return on equity of 21.52% and a net margin of 9.41%. The firm had revenue of $864.40 million during the quarter, compared to analysts’ expectations of $866.46 million. During the same quarter last year, the business earned $0.74 earnings per share. The business’s quarterly revenue was up 16.4% on a year-over-year basis.

BRKR has been the topic of a number of other research reports. The Goldman Sachs Group raised shares of Bruker from a “sell” rating to a “neutral” rating and set a $60.00 price objective on the stock in a report on Thursday, December 5th. Citigroup reduced their price objective on Bruker from $80.00 to $75.00 and set a “buy” rating for the company in a research note on Wednesday, November 6th. Wells Fargo & Company lowered their target price on Bruker from $78.00 to $75.00 and set an “overweight” rating on the stock in a research report on Wednesday, November 6th. Guggenheim restated a “buy” rating on shares of Bruker in a research report on Friday, January 17th. Finally, Wolfe Research cut Bruker from an “outperform” rating to a “peer perform” rating in a research report on Monday, September 30th. Six equities research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $74.45.

Bruker Trading Up 5.6 %

Bruker stock opened at $60.07 on Wednesday. Bruker has a 52-week low of $48.07 and a 52-week high of $94.86. The company has a market cap of $9.11 billion, a P/E ratio of 28.88, a P/E/G ratio of 3.32 and a beta of 1.17. The company has a quick ratio of 0.73, a current ratio of 1.66 and a debt-to-equity ratio of 1.24. The business has a 50-day simple moving average of $57.88 and a two-hundred day simple moving average of $61.62.

Bruker Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Monday, December 16th. Investors of record on Monday, December 2nd were issued a $0.05 dividend. The ex-dividend date was Monday, December 2nd. This represents a $0.20 dividend on an annualized basis and a yield of 0.33%. Bruker’s dividend payout ratio is presently 9.62%.

Insider Buying and Selling at Bruker

In related news, CEO Frank H. Laukien bought 100,000 shares of the business’s stock in a transaction that occurred on Monday, November 18th. The stock was bought at an average cost of $50.14 per share, with a total value of $5,014,000.00. Following the completion of the purchase, the chief executive officer now owns 38,439,563 shares of the company’s stock, valued at approximately $1,927,359,688.82. The trade was a 0.26 % increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available through this hyperlink. Insiders own 28.30% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in BRKR. American Century Companies Inc. lifted its position in shares of Bruker by 6.2% in the second quarter. American Century Companies Inc. now owns 30,223 shares of the medical research company’s stock worth $1,929,000 after buying an additional 1,776 shares in the last quarter. Envestnet Asset Management Inc. increased its stake in Bruker by 48.5% in the 2nd quarter. Envestnet Asset Management Inc. now owns 301,251 shares of the medical research company’s stock worth $19,223,000 after acquiring an additional 98,427 shares during the last quarter. Dimensional Fund Advisors LP raised its holdings in shares of Bruker by 8.6% during the 2nd quarter. Dimensional Fund Advisors LP now owns 1,277,273 shares of the medical research company’s stock worth $81,508,000 after acquiring an additional 101,539 shares in the last quarter. Vanguard Personalized Indexing Management LLC boosted its position in shares of Bruker by 7.7% during the 2nd quarter. Vanguard Personalized Indexing Management LLC now owns 9,047 shares of the medical research company’s stock valued at $577,000 after acquiring an additional 647 shares during the last quarter. Finally, XTX Topco Ltd purchased a new position in shares of Bruker in the second quarter valued at $258,000. Institutional investors own 79.52% of the company’s stock.

About Bruker

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.